Bristol Myers Squibb’s RayzeBio unit licensed exclusive global rights to Philochem's OncoACP3, a prostate cancer-targeting diagnostic and radiopharmaceutical therapeutic candidate, via a $350 million upfront deal potentially reaching $1.35 billion. This acquisition expands BMS’s radiopharmaceutical footprint following its RayzeBio acquisition, seeking to diversify treatment options with molecularly targeted approaches distinct from existing agents like Pluvicto, reinforcing BMS’s commitment to advancing innovation in oncology diagnostics and therapeutics.